Jeena Sikho Lifecare Ltd Q2 FY25 Earnings Call Analysis

- Revenue grew 74% YoY to INR 174 crores in Q1 FY '26; similar growth expected as OTC product launches scale. - EBITDA margin was strong at 45% in Q1 FY '26; management targets a healthy net profit margin of 20%-25% going forward. - PAT grew 218% YoY to INR 51 crores in Q1 FY '26; profitability expected to increase with controlled expenses and growing volumes. - Direct expenses on medicines are maintained at 15% (medicine purchase) and 9% (consumption), indicating stable cost control. - Expanding bed capacity targeting 7,000-10,000 beds in 3-5 years, implying long-term revenue growth. - OTC product launch expected to add INR 500 crores turnover in 1.5-2 years, broadening revenue base. - Operating expenses are being optimized through vendor negotiations and cost control committees, likely sustaining margin expansion. - ESOP cost impact is minor and spread over 5 years, causing minimal profitability dilution. Overall, management anticipates steady revenue growth, healthy 20-25% net margin, and improving profitability with scale and cost discipline.

The transcript does not explicitly mention the current or expected order book or pending orders for Jeena Sikho Lifecare Limited. However, relevant details indicating growth and demand include: - In Q1 FY 2025-26, 1,25,000 people took medicines; extrapolated to an estimated 5,00,000 annually if the run rate maintains. - OTC product launch on 22nd July with strong initial demand: 21 orders in the first hour, quick stock depletion in 4 days. - Plans to expand OTC turnover to INR 500 crores in 1.5 to 2 years. - Medicine sales grew from INR 63 crores in Q4 to INR 80 crores in Q1. - Hospital beds expanding rapidly with 2,570 operational beds, targeting 2,850 by March 2026. - Expansion through tie-ups with Ayurvedic colleges and plans for 7,000-10,000 beds in 3-5 years. - Profitable growth with maintained margins expected. No direct order book figure disclosed.